E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Third Quarter 2021 Financial Results on Thursday, November 4th
October 21, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the third...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Publication Reviewing the Prescribing of gammaCore for the Treatment of Cluster Headache in England
October 20, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 20, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer-reviewed paper entitled...
A743C747-1A0E-411A-BE19-027558A02AB3.png
Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device
October 19, 2021 10:03 ET | Odyssey Group International
IRVINE, CA, Oct. 19, 2021 (GLOBE NEWSWIRE) --   Odyssey Group International, Inc. (OTC:ODYY) (the "Company" or "Odyssey"), a medical technology company focused on developing unique, life-saving...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Regulatory Approval in Canada to Treat Adolescent Migraine
October 14, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 14, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that the company received an amended Medical...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Provides Business Update and Select Third Quarter 2021 Financial Guidance
October 12, 2021 08:00 ET | electroCore, Inc.
Third quarter 2021 revenue expected to be approximately $1.5 millionNet cash used to fund operations in the third quarter 2021 of approximately $3.5 million ROCKAWAY, NJ, Oct. 12, 2021 (GLOBE...
logo-brainhq-hi-res-hori.png
Brain Training takes Center Stage at NATO Symposium on Human Performance
October 07, 2021 08:00 ET | Posit Science
ROME, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Neuroscientist Dr. Michael Merzenich will be the keynote speaker on brain plasticity at a NATO symposium on Applying Neuroscience to Performance, October 11th...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Acceptance of Motion to Dismiss in the Federal Court Securities Class Action Suit
October 07, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Oct. 07, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced the granting of the company’s motion to dismiss the...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Presentation at the Cantor Fitzgerald Virtual Global Healthcare Conference
September 30, 2021 09:05 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 30, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its presentation at the...
Recognizing Tremendous Collaboration That Has 'Benefited So Many People' With Acquired Brain Injuries, Federal Judge Approves Joint Motion to Dismiss Hutchinson v. Patrick
September 29, 2021 13:47 ET | Brain Injury Association of Massachusetts
Westborough, Massachusetts, USA, Sept. 29, 2021 (GLOBE NEWSWIRE) -- The Brain Injury Association of Massachusetts (BIA-MA) today announced that U.S. District Court Judge Michael A. Posner has...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore Announces Open Access and Submission of Manuscript from SAVIOR-1 study of Non-Invasive Vagus Nerve Stimulation (nVNS) in Hospitalized COVID-19 Patients
September 29, 2021 08:00 ET | electroCore, Inc.
ROCKAWAY, NJ, Sept. 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the original author manuscript from the...